X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of X4 Pharmaceuticals (NASDAQ:XFOR) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright set a $3.50 price target on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Tuesday. Zacks Research upgraded shares of X4 Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 21st. Finally, Stifel Nicolaus set a $7.50 price target on shares of X4 Pharmaceuticals in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $33.67.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock opened at $3.75 on Friday. The company has a quick ratio of 5.48, a current ratio of 5.65 and a debt-to-equity ratio of 1.23. The stock’s fifty day moving average is $3.46 and its two-hundred day moving average is $2.97. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $26.83. The company has a market capitalization of $327.90 million, a PE ratio of -0.37 and a beta of 0.51.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10. The firm had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. As a group, analysts expect that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, Chairman Adam R. Craig purchased 86,206 shares of the stock in a transaction on Thursday, October 23rd. The shares were bought at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the transaction, the chairman owned 376,087 shares of the company’s stock, valued at $1,090,652.30. This trade represents a 29.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.37% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XFOR. Acorn Capital Advisors LLC boosted its stake in shares of X4 Pharmaceuticals by 77.8% in the third quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company’s stock worth $935,000 after acquiring an additional 119,619 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth $7,621,000. Kingdon Capital Management L.L.C. raised its position in shares of X4 Pharmaceuticals by 300.0% in the third quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after buying an additional 700,000 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals in the third quarter worth about $1,176,000. Finally, Deep Track Capital LP acquired a new position in X4 Pharmaceuticals during the third quarter worth about $3,839,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.